Napabucasin
drugOn this page
Also known as BBI-608BBI608NapabucasinaNapabucasine
Summary
Napabucasin (CHEMBL64130) is a phase-3 clinical-stage small molecule; indicated across 8 conditions including non-small cell lung carcinoma and colorectal carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 8 conditions
- Clinical trials: 24
- Chemistry: 240.21 Da · C14H8O4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL64130 |
| Name | Napabucasin |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 10331844 |
| Molecular formula | C14H8O4 |
| Molecular weight | 240.21 |
| InChIKey | DPHUWDIXHNQOSY-UHFFFAOYSA-N |
SMILES: CC(=O)C1=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O
IUPAC name: 2-acetylbenzo[f][1]benzofuran-4,9-dione
Also known as: BBI-608, BBI608, Napabucasin, Napabucasina, Napabucasine, NAPABUCASIN
Patent coverage: 325 distinct patent families (909 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 707 (78%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Aldehyde dehydrogenase 1A1, Signal transducer and activator of transcription 3.
Bioactivity
ChEMBL activities: 6 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| ALDH1A1 | 6.37 | IC50 | 425.3 | nM | CHEMBL_ACT_24348831 |
| STAT3 | 5.92 | IC50 | 1209 | nM | CHEMBL_ACT_25837030 |
| STAT3 | 5.8 | IC50 | 1586 | nM | CHEMBL_ACT_26128176 |
| STAT3 | 5.72 | EC50 | 1900 | nM | CHEMBL_ACT_18405948 |
| STAT3 | 5.7 | EC50 | 2000 | nM | CHEMBL_ACT_18405944 |
| STAT3 | 5.5 | IC50 | 3200 | nM | CHEMBL_ACT_22810899 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| non-small cell lung carcinoma | 3 | MONDO:0005233 | EFO:0003060 |
| colorectal carcinoma | 3 | MONDO:0024331 | EFO:1001951 |
| pancreatic ductal adenocarcinoma | 3 | MONDO:0005184 | MONDO:0005184 |
| colorectal neoplasm | 3 | MONDO:0005335 | MONDO:0005575 |
| hepatocellular carcinoma | 1 | MONDO:0007256 | EFO:0000182 |
| glioblastoma | 1 | MONDO:0018177 | EFO:0000519 |
| hematopoietic and lymphoid system neoplasm | 1 | MONDO:0002334 | MONDO:0044881 |
| neoplasm | 1 | MONDO:0005070 | MONDO:0004992 |
Clinical trials
Total trials: 24.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 10 |
| PHASE3 | 6 |
| PHASE1/PHASE2 | 6 |
| PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01830621 | PHASE3 | COMPLETED | BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma |
| NCT02178956 | PHASE3 | COMPLETED | A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer |
| NCT02753127 | PHASE3 | COMPLETED | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer |
| NCT02826161 | PHASE3 | TERMINATED | A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer |
| NCT02993731 | PHASE3 | COMPLETED | A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma |
| NCT03522649 | PHASE3 | UNKNOWN | A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer |
| NCT01325441 | PHASE1/PHASE2 | COMPLETED | A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies |
| NCT01776307 | PHASE2 | COMPLETED | A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer |
| NCT02024607 | PHASE1/PHASE2 | COMPLETED | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer |
| NCT02279719 | PHASE1/PHASE2 | COMPLETED | A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma |
| NCT02315534 | PHASE1/PHASE2 | COMPLETED | A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma |
| NCT02347917 | PHASE1/PHASE2 | COMPLETED | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma |
| NCT02851004 | PHASE1/PHASE2 | TERMINATED | Special Combination of BBI608 and Pembrolizumab |
| NCT03647839 | PHASE2 | COMPLETED | Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer |
| NCT01775423 | PHASE1 | COMPLETED | A Study of BBI608 in Adult Patients With Advanced Malignancies |
| NCT02231723 | PHASE1 | COMPLETED | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer |
| NCT02352558 | PHASE1 | COMPLETED | A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies |
| NCT02358395 | PHASE1 | COMPLETED | A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma |
| NCT02432326 | PHASE1 | COMPLETED | A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors |
| NCT02467361 | PHASE1 | COMPLETED | A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers |
| NCT02641873 | PHASE1 | COMPLETED | A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer |
| NCT03411122 | PHASE1 | COMPLETED | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers |
| NCT03525405 | PHASE1 | COMPLETED | A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects |
| NCT04299880 | PHASE1 | COMPLETED | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).